There is a reported trend of "heavy ai" taking over the biopharma industry. The sentiment in biopharma may have recently shifted, but the timing and implications of this shift are unclear. Some reports also mention related developments, including new insights and initiatives in the biopharma sector, as well as potential market volatility in us technology stocks.